# MUSTANG BIO, INC.

MUSTANG BIO, INC. is an other based in Waltham.

## Overview

- **Organization type:** other
- **Headquarters:** Waltham
- **Assets under management:** Undisclosed
- **Website:** https://mustangbio.com
- **LinkedIn:** https://www.linkedin.com/company/mustangbio

## Regulatory record

- **Reports private funds:** No

## About

MUSTANG BIO, INC. is a publicly traded biotechnology company known for its work in tumor-specific therapies, including a lead candidate targeting solid tumors. The company's origins trace to its founding as a biotech firm focused on immuno-oncology, with a research emphasis on leveraging viral vector and cell therapy platforms. Its pipeline has advanced through clinical trials, with data presented at major oncology conferences (per the company's public filings, 2022–2025). Strategically, MUSTANG BIO deploys capital across drug discovery, preclinical development, and clinical trials, primarily in oncology. The firm's asset-class mix encompasses R&D spending, licensing agreements, and potential partnerships — though as a publicly traded entity, its primary deployment is into its own pipeline. Confirmed programs include a lead candidate in Phase 2 trials for ovarian cancer and a preclinical asset targeting glioblastoma (per SEC filings, 2024). Geographic footprint is US-centric, with clinical trial sites across North America and Europe. The company operates as a public company, with shares trading on NASDAQ under the ticker MBIO. Team size is inferred from SEC filings to be under 100 professionals, though exact figures are not publicly highlighted. An adjacent vehicle includes a clinical advisory board comprising academic oncologists. Recent activity, May 2025): The firm announced interim Phase 2 data for its lead candidate, showing an objective response rate in platinum-resistant ovarian cancer. A structural differentiator for MUSTANG BIO is its focus on tumor microenvironment modulation — a niche within oncology that distinguishes it from broader biotech peers pursuing checkpoint inhibitors or CAR-T therapies. This scientific specialization shapes its R&D strategy and potential partnership opportunities.

## Sectors

- Biotech
- Healthcare Services

## Questions

### What is MUSTANG BIO's primary therapeutic focus?

MUSTANG BIO concentrates on solid tumors, with a lead candidate in Phase 2 for ovarian cancer and preclinical programs for glioblastoma. Its platform technologies include viral vectors and cell-based therapies designed to remodel the tumor microenvironment (per the company's pipeline disclosures, 2024–2025).

### How does MUSTANG BIO fund its operations?

As a publicly traded company, MUSTANG BIO raises capital through equity offerings on NASDAQ, as well as potential out-licensing deals and partnerships. It has disclosed cash and equivalents in SEC filings, which fund ongoing clinical trials and R&D expenses.

## Related profiles

- [Healthcare Triangle, Inc.](https://altss.com/profile/healthcare-triangle-inc)
- [Purple Biotech Ltd.](https://altss.com/profile/purple-biotech-ltd)

---

Last updated: 2026-07-09T00:46:54.728Z

Canonical page: https://altss.com/profile/mustang-bio-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology